Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Jonsson Comprehensive Cancer Center
With
OBJECTIVES: Primary * Evaluate the response rate in patients with locally advanced (stage IIIB) or metastatic (stage IV) non-small cell lung cancer treated with volociximab and erlotinib hydrochloride. Secondary * Evaluate the time to disease progression and duration of response in patients treated with this regimen. * Evaluate the safety of this drug regimen in these patients. * Evaluate the pharmacokinetics this regimen in these patients. OUTLINE: This is an open-label, multicenter study. Patients receive volociximab IV over 30 minutes once every 2 weeks and oral erlotinib hydrochloride daily for 52 weeks in the absence of unacceptable toxicity or disease progression. After completion of study treatment, patients are followed at 3 and 6 months. PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
